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In the 1960s sentinel lymph node biopsy (SLNB) was described1 
as a technique for detecting spread from parotid cancer. More 
recently it has been accepted as standard management in early 
breast cancer, but with some reservations.2,3  Axillary lymph 
node dissection (ALND) has been used as the gold standard 
for staging the axilla in patients with breast cancer.   When 
compared with ALND, SLNB may not always reflect the true 
status of the axilla.  In large series, false-negative rates of 11% 
have been noted.4,5  This decreases with the experience of the 
team. Morrow et al.6 found that when a team had performed 
SLNB in less than 10 patients, the success rate was 70%. This 
increased to 91% if the team had performed more than 30 
SLNBs.  A questionnaire sent to a random 1 000 surgeons in the 
USA showed that 30% of surgeons performed only 10 audited 
cases before relying solely on a SLNB, and 3% of surgeons 
performed no audit presuming that a SLNB performed by 
them reflected the true axillary status.7 As a result, it has been 
recommended that each surgeon (and the team involved) 
perform both a SLNB and an ALND on a number of cases 
before relying solely on a SLNB.  For example, the New Start 
programme in the UK8 trains teams around the country; after 
training the teams submit their first 30 cases as an audit. 
Surgeons working alone in private practice have financial 
constraints, making a traditional audit of patients impractical.  
We do not have the infrastructure associated with a large 
centre and are limited by the constraints of medical insurance 
companies.  If both an ALND and SNLB were performed, 
the medical insurance companies would not cover the extra 
expense of an additional procedure.  
We performed a modified audit of our first 40 cases based 
on the UK experience from the Axillary Lymphatic Mapping 
Against Nodal Axillary Clearance (ALMANAC) Trial.9  We 
modified the audit, along the lines of the current New Start 
programme, to suit our needs in private practice.  This allowed 
our patients to benefit from the SLNB technique, yet enabled 
us to validate our results.
Methods
Study population
Women with clinically node-negative breast cancer presenting 
to a single surgeon in private practice in Cape Town (JE) were 
invited to participate.  They were all asked to sign informed 
consent.  The target number of patients for the audit was 40. 
The inclusion criteria were patients with proven invasive 
breast cancer and clinically node-negative axillary examination. 
Breast cancer was diagnosed histologically with a core biopsy 
if the patient was to have a mastectomy; a triple test (cytology, 
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Background. Sentinel lymph node biopsy (SLNB) is a technique 
that is widely used in the management of early breast cancer.  
Surgeons are encouraged to validate their initial SLNB 
results by performing an audit in which both a SLNB and an 
axillary lymph node dissection (ALND) are performed.  For 
surgeons in solo private practice this is not financially viable 
as the SLNB would not be paid for by the medical insurance 
companies. 
Methods. Forty consenting patients were enrolled in the audit.  
The initial 5 patients (group A) were entered into a traditional 
audit – an ALND and a SLNB.  The next 35 patients (group 
B) formed part of a modified audit – an axillary sample was 
performed if the sentinel node was negative (group B1) and an 
ALND if the node was positive (group B2).
Results. Ninety-two per cent of patients with an ipsilateral 
sentinel axillary node on preoperative scintigraphy had their 
node identified at the time of surgery. Eight patients had 
evidence of lymphatic spread. Two patients had parasternal 
sentinel nodes which were not removed.  Group A had a mean 
of 10.8 nodes removed, group B1 5.8 nodes, and group B2 
13.2 nodes. Twenty-three of 35 patients (66%) in group B were 
spared an axillary dissection.  
Conclusion. The modified audit of group B allowed patients to 
benefit from the procedure (and thus the medical aids charged) 
and yet permitted our team to ascertain the accuracy of the 
technique in our hands.  We feel this is an approach that may 
be used by other surgeons working alone.
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radiology and clinical) in which all the results suggested a 
malignancy was considered to be diagnostic for a wide local 
excision.  In cases of an impalpable tumour or if there was 
diagnostic ambiguity, a preoperative excision biopsy was 
performed.  Exclusion criteria included evidence of axillary 
spread, pregnancy, neoadjuvant chemotherapy or tumours 
larger than 35 mm.  
The mean (± standard deviation (SD)) age was 52 ± 13 
years.  The mean tumour size was 14.4 ± 6 mm. Fourteen of the 
tumours (35%) were 10 mm or less. Thirty-one tumours (77.5%) 
were classified as ductal carcinoma, and 9 (22.5%) as lobular 
carcinoma.  
Method of sentinel node biopsy
A preoperative radionuclide scan was performed to ascertain 
the number of nodes and their position.  The scan was 
performed a day before the scheduled surgery. All patients 
were injected with 50 - 80 MBq of 99m Technetium nanocolloid 
using small volume injections of 0.3 - 0.4 ml. Injections were 
given intratumourally in patients with a palpable lump. In 
patients who had undergone excision biopsy before the scan, 
2 injections were given in subcutaneous tissue around the 
tumour site about 2 cm away from the surgical scar, on either 
side.              
A dynamic/flow study was performed after completion of 
injection of the radiotracer to demonstrate the migration of 
the radiotracer from the injection site/s as cine images. The 
study was done from the lateral view at 20 seconds per frame 
for 20 minutes, with the patient in a supine position with the 
ipsilateral arm raised above the shoulder. A set of the same 
images was done at about 2 hours post injection to confirm the 
site of the sentinel node.  After completion of delayed images, 
positions of all visible lymph nodes were marked on the skin in 
both the anterior and lateral planes.  
At the time of surgery, the pre-marked nodes were scanned 
using a portable gamma probe. After induction of general 
anaesthesia, a volume of 0.5 - 1 ml of methylene blue or Patent 
Blue V (subject to availability) was injected in the sites as 
described above.  During surgery, if a blue lymphatic channel 
was identified, it was traced and the blue sentinel node 
identified.  The gamma probe was used to confirm that the 
node was radioactive, both in vivo and ex vivo. If a blue node 
was not seen, the gamma probe alone was used to identify 
the radioactive lymph node. In case of more than 1 node, 10 
second counts for node-to-background were done.   The axilla 
was considered to be clear of all the potentially involved nodes 
when all the nodes with 10% or more of the ex vivo count of the 
sentinel node had been removed.
The nodes removed were tested for metastatic spread using 
a frozen section and cytological imprint technique. Any node 
smaller than ±8 mm (longitudinal axis) was bisected and 
imprinted on both sides; one half was frozen and sectioned. 
Larger nodes were sectioned with a microtome blade at 3 mm 
intervals, all slices were imprinted on both sides, and 1 slice 
was frozen for histological section. All intraoperative diagnoses 
were confirmed by paraffin imbedding and serial sectioning 
of all the lymph node tissue. The haematoxylin and eosin 
stain was used for both histological and cytological samples. 
Immunohistochemical cytokeratin stains (AE1/AE3) were not 
used routinely, but were performed in suspicious cases only.  
This technique represented a cost-effective and reproducible 
methodology.10
The audit was performed in two parts. The first 5 patients 
(group A) were all subjected to an ALND after identification of 
the sentinel node.  Their nodes were tested postoperatively and 
they were not charged for the procedure. The next 35 patients 
(group B) were subjected to axillary sampling if the node was 
negative (group B1) and an ALND if the node was positive for 
metastatic spread (group B2). Sentinel node sampling involved 
removing nodes from around the sentinel node.  The aim was 
to remove a total of 4 nodes.   In the case of the sentinel nodes 
being pararsternal or when the surgeon was not adequately 
convinced that the sentinel node had been found, the patient 
had an ALND.  
Statistical analysis
Analysis of the data was performed using StatXact 4.  For 
comparison of the number of nodes removed, the Wilcoxon 
rank-sum test was used.  The chi-square goodness-of-fit test 
was performed to evaluate the actual rates versus the expected 
results.
Results
Forty-one women were asked to participate.  One woman 
opted for an ALND.  Forty women took part in the audit. 
The primary breast surgery performed was mastectomy 
in 14 patients (35%) and wide local excision in 26 (65%).   
Eight patients (20%) had had a diagnostic excision biopsy 
preoperatively.  
All patients had nodes visible on the preoperative scan, 
although 1 was very faint.  Scinigraphy showed 2 patients 
to have parasternal sentinel nodes and 38 patients to have a 
sentinel node in the ipsilateral axilla. The mean time between 
preoperative injection and surgery was 23.3 ± 0.34 hours.    
Thirty-five patients (92%) with an ipsilateral axillary sentinel 
node had their node successfully located intraoperatively 
(Table I).  The 2 patients with parasternal sentinel nodes 
had an ALND.  Three patients did not have any ‘hot’ nodes 
intraoperatively.  One had her node totally replaced by 
tumour, another had her node obscured by the biopsy cavity 
in the tail of the breast, and the third patient (with a faint 
preoperative scan) had complete fatty replacement of her nodes 
histologically.  All 3 patients had an ALND (Table II).
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Of the 35 patients who had their nodes located 
intraoperatively, 28 were found to contain no evidence of 
metastases.  A total of 7 patients had evidence of metastatic 
spread to their sentinel node.  They were all from group B and 
underwent an ALND (group B2).  A mean of 13.2 ± 5 nodes 
were removed.  No patients in group A had metastatic spread 
and a mean number of 11 ± 5 nodes were removed.  In group 
B1, a mean of 6 ± 3 nodes were removed (Table III). The mean 
stay in hospital was 3.4 ± 3 days for the group that had axillary 
sampling and 6.5 ± 1 days for the group that had an ALND.
The positive predictive value of SLNB was 100%. When the 
node was successfully identified, the negative predictive value 
was 100%.  There were no significant complications related to 
the axillary surgery in either group.
Discussion
The primary role of axillary surgery in early breast cancer is 
to stage the patient’s disease status accurately.  This should be 
done with minimal morbidity.   SLNB is a technique associated 
with less complications than a standard ALND;11,12 however, 
before implementing any new technique a surgeon must be 
certain of the accuracy of the procedure in his or her hands.
In the UK, as a result of the ALMANAC trial, the New Start 
programme8 has been set up to facilitate the training of breast 
surgeons in the technique of SLNB.  The programme consists of 
a training day followed by supervision in the trainee surgeon’s 
hospital for the first 5 patients undergoing SLNB.  The surgeon 
then has to complete an audit of a further 25 cases in which 
both a SLNB and either an ALND or axillary sampling are 
performed.  This allows standardisation of the procedure. 
For surgeons working alone, it can be difficult to accrue 
the number of patients to take part in an audit where both 
an ALND and a SLNB are performed.  Private insurance 
companies cannot be expected to fund an ‘extra’ procedure. 
We performed 5 SLNB with ALND without passing the cost on 
to the patient while we standardised our approach, and then 
did a further 35 patients who had a SLNB and then had either 
axillary sampling or an ALND depending on the status of the 
sentinel node. In doing this we have modified the New Start 
training programme, which was not accessible to us in South 
Africa, in a way that allows any surgeon working alone to be 
able to demonstrate the accuracy of SLNB in their hands.  
In our practice, although a SLNB adds approximately R4 000 
($651 based on a rand/dollar exchange rate of R6.41/$ in 
February 2006) to the cost of the procedure, we have shown 
it to be cost effective.  A SLNB decreases the overall cost 
Table I. Size of tumour and SLNB results
Tumour size (mm)  Type of cancer  No. of patients  Failed  Sentinel node-positive
≤ 5   Ductal              3       1   0/2
   Lobular              0  
5 - 10   Ductal              7       2   0/5
   Lobular              4       0   1/4
10 - 20   Ductal            18       2   4/16
   Lobular              5       0   1/5
20  - 30   Ductal              2       0   0/2
   Lobular              0  
> 30   Ductal              1       0   1/1
   Lobular              0  
Total               40       5   7/35
SLNB = sentinel lymph node biopsy.    
Table II. Reasons for unsuccessful SLNB
Reason for failed identification No. of patients
Parasternal nodes              2
Node replaced by tumour             1
Obscured by biopsy cavity             1
No significant uptake             1
Total               5
SLNB = sentinel lymph node biopsy.
Table III. Number of nodes removed from patients with successful intraoperative SLNB 
   Surgery   Number of patients  No. of nodes removed (±SD)
Group A   ALND     5   10.8 (±5)
Group B (pos)  ALND     7   13.2 (±5.5)
Group B (neg)  Axillary sampling  23   5.8 (±3)
   
**Significant difference p < 0.04.
SLNB = sentinel lymph node biopsy; ALND = axillary lymph node dissection; SD = standard deviation.
}**
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of hospital admission by reducing the average number of 
days as an inpatient. In our series those who were spared an 
ALND stayed for 3 days less than those who had an ALND.  
This represented a saving of approximately R3 000 ($488) 
per patient.  Patients who did not have an ALND did not 
have a suction drain, saving a further R750 ($122).  (The cost 
of a modified radical mastectomy is approximately R20 - 
25 000 ($3 257 - 4 071), and a wide local excision and axillary 
dissection R15 - 20 000 ($2 443 - 3 257)). 
Axillary sampling is a technique that has been shown to 
accurately reflect the status of the axilla.  A consistent finding 
has been that accuracy increases if 4 or more nodes are 
removed and there is less morbidity than with an ALND.13,14 
We removed an average of 5.8 nodes (Table III) and used 
the location of the sentinel node to guide us to our area of 
sampling.  We believe it provided a reasonable assessment of 
the axillary status for audit purposes. The patients who had 
an ALND (groups A and B2) had significantly more nodes 
removed than those with axillary sampling (group B1). 
Only 8 patients had evidence of spread to the axilla.  
Silverstein evaluated the number of patients who would 
be expected to have axillary involvement and found it to 
be dependent on tumour size and whether the tumour was 
palpable at the time of presentation.14,15 Table IV looks at the 
expected and actual results. There was no significant difference 
in our results.
Ideally, a preoperative diagnosis of breast cancer is made 
without a formal excision biopsy. However, Wong et al. have 
shown that SLNB may be successfully carried out even if an 
excision biopsy has been performed.16 Eight patients had a 
prior breast biopsy. In 1 case the cavity did obscure the sentinel 
node.  The tumour was in the axillary tail.
The approach to patients whose sentinel node is in 
the internal mammary chain is controversial.  Surgically 
identifying the node is justified if the status of the node 
would change the staging of the cancer and thus the adjuvant 
treatment. Fabry et al. suggest that that is not the case.17 
However, the classification of breast cancer has been changed 
during the time of the audit to take account of the parasternal 
node status.18 We now aim to remove a parasternal sentinel 
node.
Fourteen patients had a mastectomy – 8 had multicentric 
tumours and 3 widespread ductal carcinoma in situ (DCIS). 
Three patients requested mastectomy as they did not wish to 
have radiotherapy.  SLNB has been shown to be accurate in 
patients with multicentric disease.19  
The pathological technique adopted, which included both 
intraoperative imprint cytology and frozen section of thin (2 - 3 
mm) slices of the sentinel node(s), has been shown to increase 
the sensitivity of intraoperative assessment.20 The major 
weakness of intraoperative assessment of sentinel nodes is a 
described low sensitivity for micrometastases (< 2.0 mm) and 
metastatic lobular carcinoma.21 The frozen section histological 
evaluation, in addition to the cytological evaluation assists 
in the assessment of lobular carcinoma. There were no false-
negative cases of metastatic lobular carcinoma in this group.  
Immunohistochemical cytokeratin staining was not routinely 
performed in this study, and although no false-negative cases 
of micrometastases were found, routine cytokeratin staining 
may have increased the pick-up rate, on paraffin-fixed tissue, 
for micrometastases.22 However the prognostic, predictive and 
clinical significance of occult micrometastases (< 2. 0 mm) is 
controversial.20
We have audited our first 40 SLNB patients and have done 
so while allowing the patient to benefit from the procedure.  
No patients had any complications from SLNB, and in our 
hands there were no false-positive results.  We have shown 
that a formal training programme, such as New Start, can 
be modified and applied to surgeons working in isolation 
around the world.  We feel it is a useful, safe and cost-effective 
approach that could be followed by other surgeons working 
alone in private practice thus allowing them to demonstrate the 
accuracy of SLNB in their hands.
With thanks to Dr E Panieri, Groote Schuur Hospital, Cape 
Town, South Africa.
Table IV. Comparison of expected and observed number of patients with axillary involvement
     Predicted     Expected   Observed
Tumour stage Palpable/non-palpable axillary involvement No. of patients  in sample (N)** in sample (N)**
T1a  Non-palpable               4%             1       0.04         0
  Palpable                6%             2       0.12         0
T1b  Non-palpable               7%             1       0.07         0
  Palpable                23%             10       2.30         1
T1c  Non-palpable               16%             2       0.32         1
  Palpable                31%             21       6.51         5
T2  Non-palpable    
  Palpable                48%             3       1.44         1
                  40         10.8         8
**No significant difference between these two groups (p-value = 0.8).
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